抗坏血酸：慢性肾脏病的一种有前景的药物？
Ascorbic acid: a promising agent in chronic kidney disease?
作者信息
Karahan Salih, Afsar Baris, Kanbay Mehmet
机构信息
Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Department of Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine, Isparta, Turkey.
出版信息
Clin Kidney J. 2018 Aug;11(4):530-531. doi: 10.1093/ckj/sfy044. Epub 2018 Jun 26.
Abstract
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels.
摘要
不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，与慢性肾脏病（CKD）患者的内皮功能受损及不良预后相关。此外，氧化应激和炎症也是CKD患者的常见问题，二者在CKD患者动脉粥样硬化的发生发展及心血管事件增加方面均起重要作用。维生素C可能是一种有前景的药物，可通过降低氧化应激和ADMA水平来改善CKD患者的预后。
相似文献
1
Ascorbic acid: a promising agent in chronic kidney disease?抗坏血酸：慢性肾脏病的一种有前景的药物？
Clin Kidney J. 2018 Aug;11(4):530-531. doi: 10.1093/ckj/sfy044. Epub 2018 Jun 26.
2
Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease.在慢性肾病中，抗坏血酸可降低中心血压和不对称二甲基精氨酸水平。
Clin Kidney J. 2018 Aug;11(4):532-539. doi: 10.1093/ckj/sfx158. Epub 2018 Feb 6.
3
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.不对称二甲基精氨酸（ADMA）是心血管疾病和慢性肾脏病肾损伤发生发展过程中一种新出现的危险因素。
Clin Exp Nephrol. 2007 Jun;11(2):115-121. doi: 10.1007/s10157-007-0471-x. Epub 2007 Jun 28.
4
Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.维生素E对慢性肾脏病（CKD）患者血浆不对称二甲基精氨酸（ADMA）的影响：一项初步研究。
Nephrol Dial Transplant. 2003 Nov;18(11):2415-20. doi: 10.1093/ndt/gfg406.
5
6
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.对称二甲基精氨酸（SDMA）在预测非透析慢性肾脏病的肾脏和心血管结局方面优于不对称二甲基精氨酸（ADMA）和其他甲基精氨酸。
Clin Res Cardiol. 2018 Mar;107(3):201-213. doi: 10.1007/s00392-017-1172-4. Epub 2017 Nov 3.
7
Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.非对称性二甲基精氨酸（ADMA）通过涉及胶原和 TGF-β1 合成的机制诱导慢性肾脏病。
J Pathol. 2011 Jan;223(1):37-45. doi: 10.1002/path.2769. Epub 2010 Sep 15.
8
Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.不对称二甲基精氨酸可能是心血管疾病和慢性肾病之间缺失的环节。
Nephrology (Carlton). 2007 Dec;12(6):582-90. doi: 10.1111/j.1440-1797.2007.00840.x.
9
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.慢性肾脏病中不对称二甲基精氨酸升高的分子机制及其在高血压中的作用
J Am Soc Nephrol. 2006 Aug;17(8):2176-83. doi: 10.1681/ASN.2005121379. Epub 2006 Jun 28.
10
Arginine, arginine analogs and nitric oxide production in chronic kidney disease.慢性肾脏病中的精氨酸、精氨酸类似物与一氧化氮生成
Nat Clin Pract Nephrol. 2006 Apr;2(4):209-20. doi: 10.1038/ncpneph0143.
本文引用的文献
1
Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease.在慢性肾病中，抗坏血酸可降低中心血压和不对称二甲基精氨酸水平。
Clin Kidney J. 2018 Aug;11(4):532-539. doi: 10.1093/ckj/sfx158. Epub 2018 Feb 6.
2
Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival.慢性肾脏病中的内皮抑素：与炎症、血管异常、心血管事件及生存的关联
Eur J Intern Med. 2016 Sep;33:81-7. doi: 10.1016/j.ejim.2016.06.033. Epub 2016 Jul 7.
3
Hypertension as an autoimmune and inflammatory disease.高血压作为一种自身免疫性和炎症性疾病。
Hypertens Res. 2016 Aug;39(8):567-73. doi: 10.1038/hr.2016.35. Epub 2016 Apr 7.
4
Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.尿酸和不对称二甲基精氨酸在慢性肾脏病患者心血管风险预测模型中的相关性
Int Urol Nephrol. 2016 Jul;48(7):1129-36. doi: 10.1007/s11255-016-1271-6. Epub 2016 Mar 23.
5
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.血管紧张素转换酶抑制增加维持性血液透析患者的不对称二甲基精氨酸浓度——一项随机交叉研究。
BMC Nephrol. 2015 Oct 22;16:167. doi: 10.1186/s12882-015-0162-x.
6
Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.抗高血压药物对中心收缩压和增强指数的影响：一项荟萃分析。
Am J Hypertens. 2016 Apr;29(4):448-57. doi: 10.1093/ajh/hpv134. Epub 2015 Aug 19.
7
Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials.β受体阻滞剂对内皮功能的影响：随机对照试验的荟萃分析
Cardiol J. 2015;22(6):708-16. doi: 10.5603/CJ.a2015.0042. Epub 2015 Jul 23.
8
Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients.雷米普利使血小板对一氧化氮敏感：高危患者治疗的意义。
J Am Coll Cardiol. 2012 Sep 4;60(10):887-94. doi: 10.1016/j.jacc.2012.01.066. Epub 2012 Jun 6.
9
Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.血管效应的 nebivolol 添加到氢氯噻嗪在非洲裔美国人与高血压和超声心动图证据舒张功能障碍：NASAA 研究。
J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):291-7. doi: 10.1177/1074248412436607. Epub 2012 Mar 2.
10
Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.血管紧张素转换酶抑制剂对血管内皮功能障碍的影响：一项随机对照试验的荟萃分析。
Atherosclerosis. 2011 May;216(1):7-16. doi: 10.1016/j.atherosclerosis.2011.02.044. Epub 2011 Feb 26.
Zotero 插件